Stock in the Investors Queue? Albireo Pharma, Inc. (NASDAQ: ALBO)
On 31 Jan 2020, Albireo Pharma, Inc. (NASDAQ: ALBO) changed 4.08% to recent value of $22.7. The stock transacted 140944 shares during most recent day however it has an average volume of 93.15K shares. It spotted trading -41.33% off 52-week high price. On the other end, the stock has been noted 40.73% away from the low price over the last 52-weeks.
Albireo Pharma, Inc. (ALBO) recently reported a number of advances and new initiatives in the clinical program for odevixibat, an oral once-daily capsule in development for the treatment of progressive familial intrahepatic cholestasis (PFIC), biliary atresia and Alagille syndrome. The U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug (IND) application to initiate a global pivotal trial in biliary atresia. Following planned FDA interactions in the first quarter of 2020, the company plans to commence an additional pivotal program in Alagille syndrome by the end of 2020. Management also continues to expect topline data from its Phase 3 trial in PFIC in mid-2020.
“We continue to believe in the potential for odevixibat to address unmet needs across multiple rare cholestatic liver diseases, and we remain steadfastly committed to patients and their families living with these devastating conditions,” stated Ron Cooper, Albireo’s President and Chief Executive Officer. “We expect our Phase 3 trial in PFIC will be fully randomized in the coming days, and we expect to report topline data in mid-2020. Recently, I am particularly excited to announce that the FDA has cleared our IND, and we expect to initiate a precedent-setting pivotal trial in biliary atresia in the first half of 2020. Following FDA input later this quarter, we plan to initiate a third odevixibat pivotal trial, in Alagille syndrome, later this year. We are a growing, energized and well-prepared organization, and look forward to 2020 being a transformational year for Albireo.”
The price moved ahead of -8.36% from the mean of 20 days, -1.62% from mean of 50 days SMA and performed -12.13% from mean of 200 days price. Company’s performance for the week was -1.94%, -10.70% for month and YTD performance remained -10.70%.
Vivian Moore – Health and Biotech
I am Vivian Moore, I have done my bachelor’s in English literature, and further on I did my master’s in Medicines. My most preferred genre of writing is health and biotech. I have been writing from the past 6 years about articles, web content, and blogs. In my career and education, I like to play along with work. I have also been a teacher in the past for 2 years. I use to teach business and technical writing in a very famous university. However, most recently I am working as an instructor, designer, and training writer. I enjoy socializing a lot. I am a very big extrovert when it comes to nature. A part of all this I enjoy exploring the world and traveling makes me happy.
